{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-120329","form_type":"8-K","ticker":"TSHA","cik":"0001806310","company_name":"Taysha Gene Therapies, Inc.","filed_at":"2025-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.801349+00:00","generated_at":"2026-05-21T05:31:46.267399+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Taysha secures FDA alignment on TSHA-102 pivotal trial design; Q1 net loss $21.5M","bullets":["FDA alignment on pivotal Part B trial design; IND amendment with protocol/SAP expected Q2 2025, potentially expediting registration.","TSHA-102 well tolerated: no treatment-related SAEs or DLTs in 10 patients (6 high dose, 4 low dose) as of April 10, 2025 cutoff.","Q1 2025 net loss $21.5M ($0.08/sh) vs $24.1M ($0.10/sh) in Q1 2024; cash $116.6M expected into Q4 2026.","R&D expenses $15.6M, down from $20.7M YoY due to lower manufacturing costs; G&A expenses $8.2M, up from $7.1M."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-120329","json":"https://secwatch.observer/filing/0001193125-25-120329.json","markdown":"https://secwatch.observer/filing/0001193125-25-120329.md","text":"https://secwatch.observer/filing/0001193125-25-120329.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1806310/000119312525120329/0001193125-25-120329-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1806310/000119312525120329/d89129d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T05:31:46.267399+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}